Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19/BCMA CAR T-cells”

103 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 103 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)UnknownNCT05474885
What this trial is testing

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Who this might be right for
Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
iCell Gene Therapeutics 15
Early research (Phase 1)Looking for participantsNCT07224373
What this trial is testing

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AstraZeneca 24
Testing effectiveness (Phase 2)Looking for participantsNCT06897930
What this trial is testing

Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Who this might be right for
Lupus Erythematosus, Systemic
AstraZeneca 150
Early research (Phase 1)WithdrawnNCT05513612
What this trial is testing

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)Multiple Myeloma (MM)+2 more
Shanghai Pudong Hospital
Testing effectiveness (Phase 2)Looking for participantsNCT05459870
What this trial is testing

CAR-T Cells Targeting Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute 30
Early research (Phase 1)Looking for participantsNCT07444307
What this trial is testing

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd. 18
Very early researchNot Yet RecruitingNCT06933563
What this trial is testing

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis

Who this might be right for
Myasthenia Gravis
Zhejiang University 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07451236
What this trial is testing

CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA

Who this might be right for
Transplantation Candidates With Hematological Diseases
Chang Yingjun 18
Very early researchLooking for participantsNCT07507201
What this trial is testing

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

Who this might be right for
Autoimmune DiseasesSystemic Lupus Erthematosus (SLE)Multi-Drug Resistant Nephrotic Syndrome+3 more
The Children's Hospital of Zhejiang University School of Medicine 15
Very early researchLooking for participantsNCT06976437
What this trial is testing

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Who this might be right for
B Cell LymphomaMultiple Myeloma
YANRU WANG 21
Very early researchNot Yet RecruitingNCT07423572
What this trial is testing

Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Who this might be right for
Refractory Idiopathic Membranous Nephropathy
The First Affiliated Hospital of Zhejiang Chinese Medical University 18
Very early researchUnknownNCT04617704
What this trial is testing

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Early research (Phase 1)Looking for participantsNCT07250269
What this trial is testing

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Who this might be right for
Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd. 9
Very early researchNot Yet RecruitingNCT07392528
What this trial is testing

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Who this might be right for
Neuromyelitis Optica Spectrum DisordersMultiple SclerosisMyasthenia Gravis
Tianjin Huanhu Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT05850234
What this trial is testing

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AstraZeneca 182
Very early researchLooking for participantsNCT07246096
What this trial is testing

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Sclerosis+3 more
Changhai Hospital 60
Early research (Phase 1)Looking for participantsNCT05528887
What this trial is testing

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological MalignanciesLymphomaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University 10
Early research (Phase 1)Looking for participantsNCT07295847
What this trial is testing

AZD0120 in Autoimmune Diseases

Who this might be right for
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
AstraZeneca 27
Early research (Phase 1)Looking for participantsNCT05978661
What this trial is testing

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Who this might be right for
Light Chain Amyloidosis
Nanjing University School of Medicine 12
Load More Results